Akron Children’s seeks patients with autism spectrum disorders for clinical trial


Akron Children’s Hospital is now enrolling children, teens and young adults with autism spectrum disorders in a clinical trial for a new investigational drug.

Candidates for the trial should be between the ages of 5 and 21, who have been diagnosed with an autism spectrum disorder, and exhibit certain behaviors such as listlessness and inactivity, isolation from other children and adults, fixed facial expressions or a lack of emotional response.

Participants of the study will be asked to come to an outpatient clinic at Akron Children’s seven times over five months. The visits may include a physical exam and various diagnostic tests. Parents will be asked to answer written questions and record each dose of the medication taken by their child. For each visit, a small payment will be offered to offset travel expenses.

Study participants will be randomly assigned to receive the active medication or a placebo pill in the double-blind study.

Candidates should not have any other significant medical conditions, such as heart disease, high blood pressure, lung disease, liver or kidney failure, unstable seizure disorder or thyroid disease.

“This study hopes to determine if this investigational drug can improve the social function of children with autism spectrum disorders,” said Carol Delahunty, MD, a developmental-behavioral pediatrician who is overseeing the clinical trial. “Through this research, we hope to learn to better care for patients with autism spectrum disorders.”

Akron Children’s is just one of several research centers across the country participating in the trial.

For more information about this study, call 330-543-5012.

Bookmark and Share

Developments Developments
Sign up for enewsletter
Get involved Get involved
Discover ways to support Akron Children's
Join the conversation Join the conversation
See what our patient families are saying
Twitter Pitch

Clinical trial for #autism enrolling patients 5 to 25 yrs of age

Media Contact

Holly Pupino

Laurie Scheuler